The drug consists of a cocktail, which contains the substances casirivimab and imdevimab. Both are experimental remedies created by American biotechnology specialist Regeneron.
“In a clinical trial of patients with Covid-19, casirivimab and imdevimab, administered together, were shown to reduce Covid-19-related hospitalization or emergency visits in patients at high risk of disease progression within 28 days after treatment, when compared to placebo. The safety and efficacy of this experimental therapy for use in the treatment of Covid-19 continues to be evaluated. ”
The cocktail is applied intravenously, that is, through a direct injection into the bloodstream. Now, Anvisa will have a period of 30 days to assess whether it can approve the emergency use of the drug in Brazil. The agency will use the FDA report as a basis for the opinion.
What are your expectations for the request sent by Roche to Anvisa? Tell us in the space for comments.
Get the latest news delivered to your inbox
Follow us on social media networks